Some industry watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie disagrees.
Some industry-watchers foresee biosimilars gutting Humira sales not too far into the future, though maker AbbVie disagrees. If that scenario does play out, though? The Illinois pharma has room to pare down its marketing expenses, according to one analyst.
AbbVie wants to get the most that it can out of blockbuster Humira before biosimilars in the U.S. and Europe come knocking. Part of that plan involves expanding the drug's label, and the Illinois pharma recently notched a win as the FDA approved Humira to treat a rare inflammatory skin disease.
Huge sales leaps for AbbVie's Humira have been powering revenue forecast beats for the company in recent quarters. But this time, international sales of the drug took a hit, leading the Illinois pharma to fall short of analysts' top-line expectations.
Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
With biosimilars makers eager to grab a piece of Humira's $12.5 billion-plus revenue, copies of AbbVie's blockbuster are on their way. What analysts disagree on, though, is when they'll arrive and how long it'll take them to make their presence known--and a pair of UBS analysts, for one, thinks the Illinois pharma has some marketing maneuvers up its sleeve to minimize their impact.
Here's something AbbVie doesn't want to hear: Industry watchers expect biosimilars for its top moneymaker Humira to be the most successful copycat biologics launched in the U.S. and Europe.
AbbVie is working to lessen its reliance on blockbuster Humira, which is already facing biosimilar competition in India. But it's also working to broaden the drug's label, and on that front, it got a boost from the FDA on Friday.
AbbVie's Humira is riding high, as usual--but according to the company's execs, in the U.S., it's riding higher than ever. The company's going to need to apply that market-share magic to new launch Viekira Pak, which fell short of analysts' Q1 sales estimates. But that effort is already going better than investors may think, management says.